Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection

Lucio Caccamo; Francesca Agnelli; Paolo Reggiani; Umberto Maggi; M. Francesca Donato; Stefano Gatti; Giovanni Paone; Ernesto Melada; Giorgio Rossi

doi:10.1097/01.tp.0000264001.69308.be

Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection

Lucio Caccamo, Francesca Agnelli, Paolo Reggiani, Umberto Maggi, M. Francesca Donato, Stefano Gatti, Giovanni Paone, Ernesto Melada, Giorgio Rossi

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND. Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV). METHODS. We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter. RESULTS. The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P

Original language	English
Pages (from-to)	1341-1344
Number of pages	4
Journal	Transplantation
Volume	83
Issue number	10
DOIs	https://doi.org/10.1097/01.tp.0000264001.69308.be
Publication status	Published - May 2007

Keywords

Hepatitis B virus
Hepatitis delta virus
Lamivudine
Liver transplantation
Outcome

ASJC Scopus subject areas

Transplantation
Immunology

Access to Document

10.1097/01.tp.0000264001.69308.be

Fingerprint Dive into the research topics of 'Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection'. Together they form a unique fingerprint.

Cite this

Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection. / Caccamo, Lucio; Agnelli, Francesca; Reggiani, Paolo ; Maggi, Umberto ; Donato, M. Francesca ; Gatti, Stefano; Paone, Giovanni; Melada, Ernesto ; Rossi, Giorgio.

In: Transplantation, Vol. 83, No. 10, 05.2007, p. 1341-1344.

Research output: Contribution to journal › Article › peer-review

@article{e948b568ca664d86b3ffe25a753919c4,

title = "Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection",

abstract = "BACKGROUND. Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV). METHODS. We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter. RESULTS. The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P",

keywords = "Hepatitis B virus, Hepatitis delta virus, Lamivudine, Liver transplantation, Outcome",

author = "Lucio Caccamo and Francesca Agnelli and Paolo Reggiani and Umberto Maggi and Donato, {M. Francesca} and Stefano Gatti and Giovanni Paone and Ernesto Melada and Giorgio Rossi",

year = "2007",

month = may,

doi = "10.1097/01.tp.0000264001.69308.be",

language = "English",

volume = "83",

pages = "1341--1344",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection

AU - Caccamo, Lucio

AU - Agnelli, Francesca

AU - Reggiani, Paolo

AU - Maggi, Umberto

AU - Donato, M. Francesca

AU - Gatti, Stefano

AU - Paone, Giovanni

AU - Melada, Ernesto

AU - Rossi, Giorgio

PY - 2007/5

Y1 - 2007/5

N2 - BACKGROUND. Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV). METHODS. We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter. RESULTS. The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P

AB - BACKGROUND. Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV). METHODS. We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter. RESULTS. The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P

KW - Hepatitis B virus

KW - Hepatitis delta virus

KW - Lamivudine

KW - Liver transplantation

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=34249062310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249062310&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000264001.69308.be

DO - 10.1097/01.tp.0000264001.69308.be

M3 - Article

C2 - 17519784

AN - SCOPUS:34249062310

VL - 83

SP - 1341

EP - 1344

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -